reports
- Guy Sips
- Jacob Mekhael
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
Onward Medical 2024 was a transformational year, 2025 to scale commerc...
Onward reported its FY24 business update, which underlined a lot of progress yet no major new surprises, and it reaffirms its outlook of main catalysts. Mgmt. confirmed demand is strong, but no commercial outlook was given yet. We look forward to an FDA label expansion for home use in 2025, while we also expect the pivotal Empower BP trial in blood pressure control to kick off. FY24 topline (€ 1.7m) and net result (€ -35.7m) came in line with our expectations, and with a € 60m cash position we b...
ONWARD Medical publie ses résultats financiers et opérationnels pour l...
ONWARD Medical publie ses résultats financiers et opérationnels pour l’exercice 2024 et partage ses faits marquants du début de l’année 2025 Obtention de l’autorisation de la FDA et premières ventes commerciales du système ARC-EX Investissement stratégique d’Ottobock et extension de la visibilité financière sur deux ans Obtention de droits exclusifs sur une technologie de pointe d’interface cerveau-machine EINDHOVEN, Pays-Bas, 01 avr. 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext : ONWD), société de technologie médicale développant des thérapies innovantes po...
ONWARD Medical Reports Full Year 2024 Financial and Operating Results ...
ONWARD Medical Reports Full Year 2024 Financial and Operating Results and Shares 2025 Year-to-Date Highlights Received FDA authorization and recorded first commercial sales of ARC-EX System Secured strategic investment from Ottobock and extended cash runway for two years Gained exclusive rights to premier brain-computer interface technology EINDHOVEN, The Netherlands, April 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Thomas Vranken
Onward Medical FIRST LOOK: First-in-human implant of new ARC-IM lumbar...
Onward announced the first-in-human use of its new lumbar (lower back) lead for ARC-IM, that could deliver targeted stimulation to restore lower limb mobility (e.g., standing & walking). We see this as an important clinical milestone, while we expect the company to continue to prioritize the commercial launch of ARC-EX and the start of the pivotal Empower BP trial with ARC-IM for blood pressure control. We reiterate our € 10.4 TP and Buy rating.
- Hilde Van Boxstael
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
ONWARD Medical Announces First-in-Human Use of ARC-IM Lumbar Lead Desi...
ONWARD Medical Announces First-in-Human Use of ARC-IM Lumbar Lead Designed to Restore Standing, Stepping, and Lower Limb Mobility The ARC-IM Lumbar Lead is the second model in the ARC-IM Lead family to be used in a clinical feasibility study The Company is building a portfolio of purpose-designed leads to optimize delivery of ARC-IM Therapy at various locations along the spinal cord to enable restoration of movement and other functions EINDHOVEN, the Netherlands, March 26, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative s...
ONWARD Medical Schedules Reporting of Full Year 2024 Financial Results...
ONWARD Medical Schedules Reporting of Full Year 2024 Financial Results and Business Update Webcast EINDHOVEN, the Netherlands, March 19, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces that it will report Full Year 2024 Financial Results and host a webcast to discuss business highlights. The webcast will be held on April 1, 2025, at 2:00PM CET / 08:00AM E...
- Guy Sips
- Kristof Samoy
- Lynn Hautekeete
- Thibault Leneeuw
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
Onward Medical FIRST LOOK: MJ Fox and US DoD back further development ...
Onward received grants from the Michael J. Fox Foundation ($1m) and the US Department of Defense ($1.5m) to study its ARC-IM system in Parkinson's disease. With these grants, the company aims to set up clinical feasibility studies to assess both mobility (n=56) and blood pressure instability (n=5) in Parkinson's patients. The move into Parkinson's follows an earlier case study, and could become a second pillar for Onward if positive results can be confirmed. € 10.4 TP and Buy rating reiterated.
ONWARD Medical to Advance Parkinson’s Disease Pipeline with Support fr...
ONWARD Medical to Advance Parkinson’s Disease Pipeline with Support from The Michael J. Fox Foundation and US Department of Defense The Michael J. Fox Foundation for Parkinson’s Research is supporting a study addressing mobility challenges in Parkinson’s disease; the first participant was enrolled in late 2024 A US Department of Defense grant will support a study addressing blood pressure instability; first enrollment is expected in 1H 2025 These studies both explore whether the ONWARD ARC-IM System has the potential to offer benefit beyond spinal cord injury EINDHOVEN, the Netherlands, ...
- Guy Sips
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
Onward Medical New ARC-EX study published
Spinal Research UK published the results of a new study with Onward's non-invasive ARC-EX device. Ten patients received 120 sessions of ARC-EX + rehab, showing statistically significant improvements on various endpoints for functional recovery. Improvements did not plateau after 1 year, underlining ARC-EX' game changing potential, we reiterate Buy/€10.4 TP.
ONWARD Medical Announces Publication of One-Year Study Showing Benefit...
ONWARD Medical Announces Publication of One-Year Study Showing Benefit of Sustained Access to ARC-EX Therapy Study shows significant functional improvements after one year of ARC-EX Therapy Improvements were observed throughout one-year treatment period with no plateau Results demonstrate the importance of sustained access to ARC-EX Therapy EINDHOVEN, the Netherlands, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with s...
- Guy Sips
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Thomas Vranken
Onward Medical FIRST LOOK: ARC-EX becomes available on VA procurement ...
Onward's ARC-EX system is now available on two federal procurement platforms, including the US Veterans Affairs (VA) and General Services Administration (GSA) Advantage, allowing US government clinics to purchase the system. The inclusion was facilitated by Onward's existing partnership with Lovell. The company remains on track in its commercial launch for the ARC-EX device, hence we reiterate our € 10.4 TP and Buy rating.
ONWARD Medical's ARC-EX System Now Available on US Veterans Affairs On...
ONWARD Medical's ARC-EX System Now Available on US Veterans Affairs Online Procurement Platforms ONWARD ARC-EX System for spinal cord injury is now available for purchase through VA Federal Supply Schedule and GSA Advantage platforms Partnership with Lovell Government Services is providing commercial benefit, facilitating purchase through validated US government online purchasing platforms EINDHOVEN, the Netherlands, Jan. 29, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore ...
ONWARD Medical to Present at the 43rd Annual J.P. Morgan Healthcare Co...
ONWARD Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference CEO Dave Marver to Provide Company Update Wednesday, January 15, 2025 EINDHOVEN, the Netherlands, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces that CEO Dave Marver will present a company update at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, Janu...
- Thomas Vranken
Onward Medical FIRST LOOK: First commercial sales for ARC-EX
Only days after its de novo FDA approval for ARC-EX in clinic use, Onward has realized its first sales of the device. The two initial customers are UW Medicine and Next Steps Chicago, which appears in line with the company's previously communicated limited launch strategy. We look forward to seeing more sales materialize over the year. We reiterate our € 10.4 TP and Buy rating.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.